Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02024932 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02024932 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 37 participants.
The verdict
NCT02024932, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).
Interventions
- DRUG Placebo
- DRUG BVS857
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2014-02-04 |
| Est. Completion | 2016-04-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02024932
The ClinicalTrials.gov registry entry for NCT02024932 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02024932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02024932 about?
NCT02024932 is a clinical study titled "Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy". The purpose of this study was to determine if BVS857 is safe, tolerable and increases thigh muscle thickness in patients with spinal bulbar and muscular atrophy (SBMA).
What is the current status of trial NCT02024932?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2014-02-04. Estimated completion is 2016-04-13.
What interventions are being tested in trial NCT02024932?
The interventions under investigation include: Placebo (DRUG), BVS857 (DRUG).
Who is sponsoring clinical trial NCT02024932?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.